Dr. Elisabet E. Manasanch
Claim this profileM D Anderson Cancer Center
Studies Plasma Cell Neoplasm
Studies Multiple Myeloma
8 reported clinical trials
9 drugs studied
Area of expertise
1Plasma Cell Neoplasm
Stage III
Stage IV
2Multiple Myeloma
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Elisabet E. Manasanch is currently running
Belantamab Mafodotin
for Multiple Myeloma
This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. The study will have a dose-finding part and a dose-expansion part. The maximum number of enrolled patients will be 30 with 18 patients for the dose-finding part and 12 patients for the dose-expansion part. Once we determine the MTD or RP2D in the dose-finding part, we will enroll and treat 12 additional patients at the MTD or RP2D in the expansion part. Efficacy will be assessed through the overall response rate (ORR) at the end of the study. With the limited number of patients for the dose-expansion part, we will not have formal futility monitoring rule.
Recruiting1 award Phase 110 criteria
Isatuximab
for Multiple Myeloma
This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Fifty adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc will be enrolled across 2 sites, The University of California San Francisco and The University of Texas MD Anderson Cancer Center. Consented participants will be enrolled in a 3-month digital health coaching program through which electronic patient reported outcomes and wearable activity data will be collected. Outcomes include treatment experience, quality of life, financial toxicity, treatment adherence, symptom burden and health self-efficacy. These will be captured by patient reported outcome measures including the Patient's Qualitative Assessment of Treatment- Real World (PQAT-RW), Patient Global Impression of Change/Severity (PGIC/S), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), Quality of Life Questionnaire Multiple Myeloma (QLQ-MY20), and the European QoL-5 Dimensions (EQ5D), Cancer Behavior Inventory-Brief Form (CBI-B), Center for Adherence Support Evaluation (CASE) Medication Adherence Index, Comprehensive Score for Financial Toxicity (COST) Instrument. Clinical data, including treatment history, healthcare utilization, and co-morbidities, as well as demographic data will be collected via the electronic health record from each clinical site. This data will be complemented by qualitative data from a selected cohort of study participants with a focus on treatment experience ranging from infusion burden, toxicity management, to overall quality of life. Evaluation of this data in combination will be used to better understand the treatment experience of individuals on standard of care isatuximab-irfc specifically, and with relapsed or refractory multiple myeloma generally, contributing to an existing gap in the literature regarding patient reported outcomes from diverse data sources. Outcomes will be analyzed with attention to the relationship between social determinants of health, including race, ethnicity, and geographic location, and treatment experience as reflected in both the qualitative and quantitative data.
Recruiting1 award N/A6 criteria
More about Elisabet E. Manasanch
Clinical Trial Related6 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Elisabet E. Manasanch has experience with
- Isatuximab
- Lenalidomide
- Dexamethasone
- Daratumumab
- Belantamab Mafodotin
- Vaccine Therapy
Breakdown of trials Elisabet E. Manasanch has run
Plasma Cell Neoplasm
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Elisabet E. Manasanch specialize in?
Elisabet E. Manasanch focuses on Plasma Cell Neoplasm and Multiple Myeloma. In particular, much of their work with Plasma Cell Neoplasm has involved Stage III patients, or patients who are Stage IV.
Is Elisabet E. Manasanch currently recruiting for clinical trials?
Yes, Elisabet E. Manasanch is currently recruiting for 3 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Elisabet E. Manasanch has studied deeply?
Yes, Elisabet E. Manasanch has studied treatments such as Isatuximab, Lenalidomide, Dexamethasone.
What is the best way to schedule an appointment with Elisabet E. Manasanch?
Apply for one of the trials that Elisabet E. Manasanch is conducting.
What is the office address of Elisabet E. Manasanch?
The office of Elisabet E. Manasanch is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.